By Justin Petrone

Increasing demand for target enrichment products and cytogenetic arrays helped Roche NimbleGen post a 22 percent rise in third-quarter revenue, the firm said last week.

In comparison, Roche's broader Applied Science business, a segment of the company's diagnostics division that encompasses Roche NimbleGen, decreased 2 percent during the third quarter, while the diagnostics division grew 1 percent and company-wide sales were down 7 percent for the quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.